Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

Moderna, Inc. (NASDAQ:MRNA) is a pharmaceutical and biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. The company gained widespread recognition for its COVID-19 ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other most promising gene editing stocks to buy according to hedge funds. The pharmaceutical ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

On Thursday, Moderna Inc (NASDAQ:MRNA) stock is trading higher after the company reported better-than-expected third-quarter ...